CAPA Survival Playbooks — Kandih Bioscience CAPA does not sit in QA.From an FDA inspection perspective, CAPA sits at the intersection of complaints, design controls, supplier/CMO oversight, and management review. If CAPA is positioned downstream—after complaints are closed, designs are frozen, or suppliers are “handled”—inspectors interpret the system as reactive and ineffective, regardless of documentation […]
Author: admin
Where Do Your CAPAs Originate Most?
CAPA Survival Playbooks — Kandih Bioscience CAPAs Don’t Fail at Closure—They Fail at the Source Most CAPA programs don’t fail because teams can’t write corrective actions.They fail because organizations never ask—or cannot clearly answer—a far more uncomfortable question: Where do our CAPAs actually come from? Inspection after inspection, FDA sees the same pattern: CAPAs are […]
CAPA ≠ Paperwork. It’s a Risk-Control Feedback Loop
CAPA Survival Playbooks — Kandih Bioscience One of the most common inspection surprises plays out the same way every time:the CAPA file is immaculate—signed, dated, closed on schedule—yet the inspection ends with a Form 483. That disconnect is not subtle. It reflects a fundamental misunderstanding of what CAPA is designed to do. Many organizations still […]
CAPA Failures as Evidence of a Broken Risk-Control System
(How FDA documents system collapse, not paperwork gaps) FDA consistently uses CAPA failures as proxy evidence that a firm’s end-to-end risk-control architecture is nonfunctional. For medical devices, this is most often cited as a violation of 21 CFR 820.100(a). For drugs and combination products, the same systemic failure is documented through CGMP investigation and CAPA […]
Why FDA Treats CAPA as a Risk-Control System, Not a QA Task
The CAPA Operating System (System-Level Reality) Most CAPA programs don’t fail because of weak documentation.They fail because they were never architected as systems. Organizations routinely design CAPA as a QA artifact—a form, a workflow, a closure event. FDA inspects something very different: a live, end-to-end risk-control system that proves an organization can detect, absorb, and […]
Disseminated Intravascular Coagulation – Causes
DIC is caused by another medical condition that makes the body’s normal blood clotting process become overactive. The condition progresses through two stages. In the early stages, overactive clotting leads to blood clots throughout the blood vessels. The clots can reduce or block blood flow, damaging organs.
As DIC progresses, the overactive clotting uses up platelets and clotting factors, which are protein that help with normal blood clotting. Without these platelets and clotting factors, DIC can cause bleeding just beneath the skin, in the nose or mouth, or deep inside the body
Fifty Salmonella Recalls Later: What the Frozen Food Industry Still Isn’t Getting About Safety
A Toxicologist’s Take on Why This Was Predictable—and Preventable
According to NewsNation, a New Jersey–based frozen food distributor has issued more than 50 recall notices after multiple products were linked to Salmonella contamination. The scope is extraordinary: dozens of products, multiple brands, nationwide distribution, and exposure across vulnerable populations.
(Source: NewsNation, 2025)
This is not just another recall story.
Seldane & Astemizole: The Antihistamines That Rewired Cardiac Safety Forever
How QT Prolongation, hERG Blockade, and Drug Interactions Forced a Regulatory Reset
In the late 1990s, two blockbuster “non-sedating” antihistamines—terfenadine (Seldane) and astemizole—were pulled from the market after being linked to QT interval prolongation and torsades de pointes, a rare but often fatal heart rhythm disturbance.
Baycol (Cerivastatin): The Statin That Taught Pharma a Billion-Dollar Toxicology Lesson
How Muscle Toxicity, Drug Interactions, and Design Blind Spots Led to a Global Withdrawal
In 2001, Bayer withdrew cerivastatin—marketed as Baycol in the U.S. and Lipobay internationally—after mounting reports of rhabdomyolysis, a severe form of muscle breakdown that can lead to acute renal failure and death.
The consequences were immediate and severe: a global recall, thousands of adverse event reports, over 50 confirmed deaths, multibillion-dollar litigation settlements, and long-term reputational damage that weighed heavily on Bayer’s valuation for years.